Theriva Gets Orphan Drug Designation for VCN-01 to Treat Pancreatic Cancer

By Stephen Nakrosis

Theriva Biologics on Tuesday said the U.S. Food and Drug Administration granted orphan drug designation to its lead clinical candidate, VCN-01, as a treatment for pancreatic cancer.

An ongoing clinical study is evaluating intravenous VCN-01 in combination with standard-of-care chemotherapy as a first line therapy for certain pancreatic cancer patients, the company said. The FDA previously granted orphan drug designation to VCN-01 to treat retinoblastoma, a cancer affecting the eyes.

The FDA grants orphan drug designation to products which prevent, diagnose or treat a rare disease or condition.

Write to Stephen Nakrosis at [e-mail]

(END) Dow Jones Newswires

06-27-23 1705ET